Trade name Farxiga

Oral agent to treat type 2 diabetes

Approved for glycemic control, along with diet and exercise, in adults with type 2 diabetes.

Approved as combination with metformin.extended-release, called Xigduo XR.

Inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney.

In clinical trials lowers HbA1c by 0.90 percentage points when added to metformin.

Heavy glycosuria can lead to rapid weight loss, tiredness, polyuria, and can lead to dehydration.

Glycosuria can also worsen the infections already associated with diabetes, such

as urinary tract infections and candidiasis.

Associated with hypotensive reactions.

Does not interfere with intestinal glucose absorption.

Among patient with heart failure and reduced for ejection fraction, the risk of worsening heart failure or death was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes (McMurrayJ).

Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and mildly reduced or preserved ejection fraction (DELIVER Trial Committees and investigators).

Dapagliflozin compared with placebo, when added to recommended therapy, significantly reduces the risk of worsening heart failure or cardiovascular death independent of diabetic status.
Dapagliflozin Use among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of  a sustained decline in estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes was significantly lower with dapagliflozin than with placebo (DAPA-CKD TRALI).


Leave a Reply

Your email address will not be published. Required fields are marked *